PMID- 21827391
OWN - NLM
STAT- MEDLINE
DCOM- 20120604
LR  - 20211203
IS  - 2212-3938 (Electronic)
IS  - 1574-8847 (Linking)
VI  - 6
IP  - 3
DP  - 2011 Aug
TI  - Immunotherapy and targeted therapy combinations in renal cancer.
PG  - 207-13
AB  - In recent years an improved understanding of renal cell carcinoma (RCC) tumor 
      biology has translated into major advancements in the treatment of patients with 
      metastatic RCC. These novel therapies include inhibitors of the vascular 
      endothelial growth factor (VEGF) pathway, and inhibitors of the mammalian target 
      of rapamycin (mTor) pathway. In contrast to the results seen with molecularly 
      targeted therapies, the administration of high-dose bolus IL-2 (HD IL-2) can 
      produce durable responses in a small percentage of patients. While the 
      substantial toxicity and limited efficacy that is associated with HD IL-2 limits 
      its application, novel immunotherapies may be able to produce durable benefit 
      with less toxicity. Once the standard of care, the role of low-dose single-agent 
      cytokines is now limited in patients with RCC. However, combinations of cytokines 
      with targeted therapy may have merit. The advent of targeted therapy in RCC does 
      not eliminate the potential utility of immunotherapy but rather requires a 
      rational refinement of this approach through improvements in patient selection 
      and combination therapy that may increase the cure rate for patients with this 
      disease.
FAU - McDermott, David F
AU  - McDermott DF
AD  - Biologic Therapy Program, Beth Israel Deaconess Medical Center, Boston, MA, USA. 
      dmcdermo@bidmc.harvard.edu
LA  - eng
GR  - P50 CA101942-01/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United Arab Emirates
TA  - Curr Clin Pharmacol
JT  - Current clinical pharmacology
JID - 101273158
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Interleukin-2)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/administration & dosage
MH  - Carcinoma, Renal Cell/*drug therapy/*immunology
MH  - Drug Delivery Systems/methods/*trends
MH  - Humans
MH  - Immunotherapy/methods/*trends
MH  - Interleukin-2/immunology
MH  - Kidney Neoplasms/*drug therapy/*immunology
MH  - T-Lymphocytes/drug effects/immunology
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/immunology
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors/immunology
EDAT- 2011/08/11 06:00
MHDA- 2012/06/05 06:00
CRDT- 2011/08/11 06:00
PHST- 2011/01/24 00:00 [received]
PHST- 2011/03/13 00:00 [accepted]
PHST- 2011/08/11 06:00 [entrez]
PHST- 2011/08/11 06:00 [pubmed]
PHST- 2012/06/05 06:00 [medline]
AID - BSP/CCP/E-Pub/0050 [pii]
AID - 10.2174/157488411797189451 [doi]
PST - ppublish
SO  - Curr Clin Pharmacol. 2011 Aug;6(3):207-13. doi: 10.2174/157488411797189451.